Kiora Pharmaceuticals Inc. (KPRX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kiora Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SE Sima Elimelech Activest Wealth Management | 2 | $8.4 | $5.2 | -$3.2 | -38.1% |
| BM Bert Miller Miller Wealth Advisors LLC | 1,000 | $1,970 | $2,620 | $650 | 32.99% |
Kiora Pharmaceuticals Inc. (KPRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kiora Pharmaceuticals Inc. ever had a stock split?
Kiora Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Strem CEO | NASDAQ (CM) Exchange | 49721T101 CUSIP |
| US Country | 12 Employees | 30 Aug 2019 Last Dividend | 11 Jun 2024 Last Split | 31 Jul 2015 IPO Date |
Overview
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative therapies for the treatment of ophthalmic diseases. Originally known as Eyegate Pharmaceuticals, Inc., the company underwent a name change to Kiora Pharmaceuticals, Inc. in November 2021, signaling a new phase in its development strategy. Since its incorporation in 1998, Kiora has been dedicated to addressing the unmet needs within the realm of eye diseases, leveraging advanced scientific research to tackle some of the most challenging ophthalmic conditions. With its headquarters in Encinitas, California, Kiora Pharmaceuticals is positioned at the forefront of ophthalmic treatment innovation in the United States.
Products and Services
- KIO-301 - This leading product candidate represents a groundbreaking approach to restoring vision. Currently in Phase 1b clinical trials, KIO-301 is a small molecule designed as a photoswitch, aimed at reversing vision loss caused by both inherited and age-related degenerative retinal diseases. By enabling light-sensitive control of neuron activity, it promises to offer a novel solution for patients suffering from severe visual impairment.
- KIO-101 - This innovative eye drop is targeting the ocular manifestations of rheumatoid arthritis. Now in Phase 2 clinical trial, KIO-101 seeks to alleviate the inflammatory effects of the disease within the eye, offering relief and improved eye health to sufferers of this chronic autoimmune condition.
- KIO-104 - Focused on the treatment of posterior non-infectious uveitis, an inflammation of the uvea in the eye, KIO-104 is under development to provide a targeted therapy option. This condition, if left untreated, can lead to severe vision loss, making the potential impact of KIO-104 significant for those affected.
- KIO-201 - As a therapeutic eye drop in Phase 3b clinical trials, KIO-201 is aimed at patients undergoing photorefractive keratectomy (PRK) surgery. This product is designed to assist in corneal wound repair post-surgery, potentially reducing recovery time and improving outcomes for patients undergoing this common form of vision correction surgery.
